Inhibition of telomerase activity in malignant glioma cells correlates with their sensitivity to temozolomide.
about
Elucidation of the function of type 1 human methionine aminopeptidase during cell cycle progressionTranscription Regulation of the Human Telomerase Reverse Transcriptase (hTERT) GeneTherapeutic Targeting of TelomeraseCharacterization of a novel anti-cancer compound for astrocytomasThe human RECQ1 helicase is highly expressed in glioblastoma and plays an important role in tumor cell proliferation.The DNA methylation inhibitor induces telomere dysfunction and apoptosis of leukemia cells that is attenuated by telomerase over-expression.Telomerase: a potential therapeutic target for cancer.The neuro-steroid, 3beta androstene 17alpha diol exhibits potent cytotoxic effects on human malignant glioma and lymphoma cells through different programmed cell death pathwaysGANT61, a GLI inhibitor, sensitizes glioma cells to the temozolomide treatment.Synergistic suppression of noscapine and conventional chemotherapeutics on human glioblastoma cell growth.Current evidence of temozolomide and bevacizumab in treatment of gliomas.Delivery of a drug cache to glioma cells overexpressing platelet-derived growth factor receptor using lipid nanocarriersShikonin and its derivatives inhibit the epidermal growth factor receptor signaling and synergistically kill glioblastoma cells in combination with erlotinib.Silencing of the hTERT gene through RNA interference induces apoptosis via bax/bcl-2 in human glioma cellsHFE polymorphisms influence the response to chemotherapeutic agents via induction of p16INK4A.Effect of temozolomide on the viability of musculoskeletal sarcoma cells.Application of an assay Cascade methodology for a deep preclinical characterization of polymeric nanoparticles as a treatment for gliomas.MDM2 Degrades Deacetylated Nucleolin Through Ubiquitination to Promote Glioma Stem-Like Cell Enrichment for Chemotherapeutic Resistance.BICD1 expression, as a potential biomarker for prognosis and predicting response to therapy in patients with glioblastomas.Polymer-Temozolomide Conjugates as Therapeutics for Treating Glioblastoma
P2860
Q24673593-57F9F543-E370-4F65-9FAB-807B27E4FF47Q26739925-E58A5D5C-1EF2-4785-A705-AB1AFCBE9B22Q26741736-22757B35-3776-47C5-8BB7-773D6F1BDEC5Q28543237-C61561A2-84A1-415F-B168-E6C671E50649Q35142283-98348915-3EF8-4F40-87CD-D9E9981D4F86Q35741571-E525D249-3F9A-4E7D-B2A6-1BBFB864D40DQ36158693-B09AF7C5-5AD5-453C-873F-086636480FF6Q36611032-A7C4C36E-C3B4-49FC-9150-B3D19EC5ECA2Q37450330-5F8EBDBE-A4F2-4B1E-821C-9AF3E48A6B48Q37728530-411EDC03-C3E0-4606-ADE4-B5A5AD2121F5Q38230650-5EEC86ED-DB7F-48EA-9EDD-C03624917129Q38784169-D477006F-FF20-4B27-B003-5D2A992C8C3DQ38908815-351031A8-A969-4BE4-88D0-F6865533E915Q39296941-2026F03F-5752-4932-B5EC-850863C500F0Q39614785-B98BB604-24DD-4453-8D91-7ADDDEF6E58CQ40257600-90616F1F-8291-490F-A69C-C333F842451CQ48089996-6B9D30D6-06E9-4701-A0D3-510C3F63D345Q48181924-C4DC4394-5B3B-419B-BC51-1333D5D6DF56Q49640790-9EE57285-C645-44F6-B5B8-573BA492B1B8Q57814961-8F35FE45-A30D-47A2-A329-8BAB726A9468
P2860
Inhibition of telomerase activity in malignant glioma cells correlates with their sensitivity to temozolomide.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Inhibition of telomerase activ ...... r sensitivity to temozolomide.
@ast
Inhibition of telomerase activ ...... r sensitivity to temozolomide.
@en
type
label
Inhibition of telomerase activ ...... r sensitivity to temozolomide.
@ast
Inhibition of telomerase activ ...... r sensitivity to temozolomide.
@en
prefLabel
Inhibition of telomerase activ ...... r sensitivity to temozolomide.
@ast
Inhibition of telomerase activ ...... r sensitivity to temozolomide.
@en
P2093
P2860
P356
P1476
Inhibition of telomerase activ ...... ir sensitivity to temozolomide
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BJC.6601193
P407
P577
2003-09-01T00:00:00Z